FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.
Alzheimer’s Association asks CMS to provide full coverage of FDA-approved dementia drugs
By
Kimberly Bonvissuto
Dec 21, 2022
Every day, more than 2,000 older adults living with mild dementia may transition to a more advanced stage of the disease and no longer be eligible for lecanemab and other antibodies targeting amyloid under...
Progress made in Alzheimer’s research and lifestyle interventions, NIH says
By
Kimberly Bonvissuto
Nov 30, 2022
The burden of Alzheimer’s disease and related dementias is significant, according to the National Institutes of Health. But scientists have made progress in drug development, lifestyle interventions,...
Living with others, being engaged slow cognitive decline: study
By
Kimberly Bonvissuto
Oct 27, 2022
Living with others, weekly community group engagement and interaction with family and friends, and never feeling lonely are associated with slower cognitive decline, according to the results of a new study.
Raise grant rates for assisted living, wages and benefits for caregivers, board recommends
By
Kimberly Bonvissuto
Oct 05, 2022
A state government advisory board is recommending that the Virginia General Assembly increase grant awards to cover assisted living costs, mandate sick leave and a living wage for direct care workers,...
New drug for Alzheimer’s disease shows promise in phase 3 trial
Sep 28, 2022
Lecanemab is a monoclonal antibody drug designed to target and help remove Alzheimer’s-associated amyloid plaques in the brain.
Older adults with cognitive impairment at risk for financial exploitation: study
By
Kimberly Bonvissuto
Sep 15, 2022
Among the estimated 50 million adults 65 and older in the nation, 20% have a form of cognitive impairment. And many of those individuals live alone and are having difficulty managing their finances, leaving...
‘Significant’ drop in residential care aide workforce during pandemic raises questions about future...
By
Kimberly Bonvissuto
Sep 08, 2022
The residential care aide workforce — personal care aides, home health aides and nursing assistants who work in assisted living communities, continuing care retirement / life plan communities and other...
Effect of noradrenergic drugs explored in Alzheimer’s disease
Jul 29, 2022
Meta-analyses suggest positive effects of noradrenergic drugs on global cognition and apathy.
Exercise, chores, social visits linked to lower dementia risk
Jul 28, 2022
Comparable results were seen for dementia, vascular dementia, Alzheimer’s disease, and in analyses stratified by dementia polygenic risk score.